A data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians aims to help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.
MD Anderson Cancer Center and Yingli Pharma US Inc. entered a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors.
A collaborative research team led by scientists from Roswell Park Comprehensive Cancer Center and Wake Forest University Baptist Medical Center has determined that a GTPase called RAC1 actively recruits enzymes involved in nucleotide production to promote cancer metastasis.
Researchers from Jonsson Comprehensive Cancer Center at UCLA have illuminated molecular “crosstalk” in pancreatic cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.
For patients with acute lymphoblastic leukemia carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation, the two-year overall survival rate nearly doubled from 2000-2004 to 2015-2019, according to a study published in Clinical Cancer Research.
Researchers in Purdue University’s College of Pharmacy are further developing a potential immunotherapy treatment for cancer, one focused on the mutation of the PTPN22 enzyme.
The National Comprehensive Cancer Network published NCCN Guidelines for Patients: Graft-Versus-Host Disease, weeks after Orencia became the first drug approved by FDA for the prevention of GVHD (The Cancer Letter, Dec. 17, 2021).
The National Comprehensive Cancer Network has published updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer.
A three-drug combination could help patients with aggressive forms of blood cancer achieve longer cancer remission after undergoing allogeneic stem cell transplantation, according to preliminary clinical trial results presented by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
